Depression under stress: ethical issues in genetic testing (Refereed Editorial) by Newson, A.J.
1 |  P a g e
 
Postprint 
This is a pre-copyedited, author-produced PDF of an article accepted for publication in [British Journal of 
Psychiatry] following peer review. The definitive publisher-authenticated version [Newson, A.J. (2009) 
“Depression under stress: ethical issues in genetic testing (Refereed Editorial).” British Journal of Psychiatry, 
195: 189-190.] is available online at http://bjp.rcpsych.org/content/195/3/189.abstract?sid=72749392-0051-
4746-8310-43a0cbbf3431  
 
Editorial: 
Depression under stress: ethical issues in genetic testing 
Ainsley J. Newson, PhD, 2009 
   
Abstract 
Summary: Genetic testing for risk of depression requires a reconsideration of ethical issues in 
genetics and how they manifest in psychiatric practice. A precautionary approach is advocated in 
that there should be limits on the use of the 5-HTT genetic test until its clinical utility and broader 
social impact are better understood. 
 
The long-heralded promises of genetic research into complex human behaviours are, it seems, 
coming a step closer. Increasing numbers of candidate genes associated with mental illness are 
being published and results replicated by other research teams. Surveys in patient and lay groups 
have demonstrated significant interest in accessing genetic testing to predict or partially explain 
one's mental health. A recent paper in the Journal provides one of the first retrospective 
investigations of the impact of receiving genetic information associated with a risk of depression 
under stress (hereinafter ‘depression’).1 
Yet so far, something is missing. Although the ethical implications of psychiatric genetic research and 
its clinical application have been discussed in the literature, this takes a generalist, prospective and 
speculative view.2-5 With a couple of exceptions, there is scant literature analysing the ethical 
implications of genetic testing for risk of depression.6,7 No detailed ethical analysis of returning 
research results or the clinical application of the 5-HTT gene test has been published. 
This absence from the literature is interesting, given that the 5-HTT test has been possible for some 
time. It may be that no new ethical issues arise beyond those already debated. Considerations of 
genetic exceptionalism, genetic determinism, family communication and the ‘right not to know’ are 
certainly interesting but are not unique to psychiatric genetics. However, the move from Mendelian 
to complex genetics may necessitate a re-analysis of existing issues, integrating the ethical aspects of 
genetic, clinical and environmental factors.8 Psychiatry is also arguably a unique branch of medicine 
in that it involves the interplay between values, science and clinical judgement.7 Introducing 
molecular data to explain what some may see as their ‘true self’ could give rise to challenges to self-
understanding. 
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To whom and how should this test be offered? 
Nearly two-thirds of Wilhelm et al's cohort consented to the 5-HTT genetic test;1 a higher rate than 
that observed for single-gene conditions such as Huntington's disease. This result is consistent with 
studies that predicted high levels of interest in psychiatric genetic testing. It may indicate that 
receiving genetic information about depression is not as threatening as for life-limiting diseases, or 
that this low-risk susceptibility gene will not be over interpreted as determinative of depression risk. 
However, the cohort tested were an expert group (having been involved in a longitudinal study of 
depression) past the mean age at onset for depression. This uptake rate may therefore represent an 
upper threshold. 
Depending on the mechanism of access, whether through a clinic or directly to consumers, a genetic 
test for risk of depression could be offered as a pre-symptomatic test or as a tool to aid diagnosis. It 
might be offered to individuals who have experienced depression, those with a family history, or 
anyone at all. The test may have most relevance for those who have experienced depression, yet if 
individual autonomy is emphasised there is potential for any individual to choose to obtain this 
information to enhance their self-knowledge or to inform long-term plans.7 This wide offer may, 
however, cause an overemphasis on genetic factors in risk of depression. 
Protocols for offering this test require consideration. First, should pre- and post-test counselling be 
offered or mandatory? This test provides a probabilistic result and requires careful explanation. 
Without significant prior knowledge, could this be achieved by telephone or online? Second, test 
recipients in this study were presumably able to access the test free of charge and did not have to 
attend clinic to obtain results.1 The test will almost certainly attract a charge in many health systems 
and will require rigorous evaluation to be offered through any nationally funded health service. 
The test may not only be relevant to competent consenting adults. If pre-symptomatic interventions 
become available, the 5-HTT test could become relevant to younger people, in particular children 
and adolescents.2,6 It could be used as a tool for pre-symptomatic identification of children or 
young adolescents with the s/s or s/l genotype and to provide advice about avoiding environmental 
stress. But this testing regime would only be effective for population health by way of screening. 
Such a programme is unlikely to be introduced with present levels of efficacy and utility of this test, 
the lack of knowledge of gene environment interactions and predictability of illness onset or 
severity. There are also recommendations against testing children for psychiatric conditions in the 
absence of a clear intervention 4 and unresolved ethical concerns such as the impact on the parent-
child relationship and the child's developing sense of self.6 
The potential application of psychiatric genetic testing in prenatal diagnosis has also been 
recognised.2 Depression can be a debilitating illness and some couples with experience of this 
condition may wish to avoid passing it on to their children. But it would be premature to offer 
prenatal diagnosis for 5-HTT, for practical and ethical reasons. Practically, the 5-HTT gene is a 
measure of risk, not certainty. An s/s genotype is no indication of the certainty of depression, nor its 
severity.7 Ethically, there needs to be further debate on the level of absolute increase in risk of 
depression (if any) that would be a justifiable threshold for offering prenatal diagnosis.3 Many 
couples may actually be trying to avoid the stigma of the illness rather than the illness itself, which, if 
managed well, may not have an adverse impact on an individual's life. Public and patient education 
to reduce stigma is also required. 
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Who should offer this test should also be considered. Commercial genetic testing for some mental 
illnesses is already available and there is bound to be interest in this test as well. Some commercial 
providers offer pre- and post-test counselling; others adopt a more technical approach. Direct-to-
consumer genetic testing has given rise to concerns of misinformation, but this is yet to be 
definitively established. Regulating commercial provision of any genetic test is difficult and is often 
limited to monitoring marketing and advertising. Yet given the complexity and limitations of this 
information, a thorough pre-test workup, establishing understanding and reinforcing the importance 
of reflecting on personal resilience and coping style 1 should be provided face to face in a clinical 
environment. 
Mitigating adverse outcomes 
If this test is to be offered more widely, steps must be taken to ensure that adverse outcomes are 
monitored and minimised. Perceptions of mental health can form an important component of our 
sense of self. Those receiving s/s results in Wilhelm's study had significantly higher levels of distress 
and expectation of a future episode of depression than did those receiving s/l or 1/1 results,1 which 
begs the question of whether the experience of genetic testing per se could trigger a depressive 
episode. This potential for a ‘self-fulfilling prophecy’ is possible but can be mitigated by careful 
framing of information during pre- and post-test counselling. 
The risk of genetic determinism - of attributing all health and behaviour to genetic causes - appears 
low from this study. Indeed, participants felt that genetics was a less important determinant of risk 
of depression after having the test than they did beforehand - possibly due to the careful 
explanation of results or the increasing public incorporation of genetic information into explanations 
of health and illness.8 However, further mixed-methods survey-based studies should monitor 
whether test recipients feel that a diagnosis is more conclusive or permanent if arising from DNA 
analysis than clinical diagnosis. 
Privacy and confidentiality of results should also be carefully controlled and access by third parties 
such as insurers and employers should be strictly regulated.4 Discrimination by such bodies is by no 
means a certainty, but the ongoing stigmatisation of mental illness 9 means that policy-makers 
cannot become complacent.3 
Future directions 
The 5-HTT gene is unlikely to become the sine qua non to managing depression. However, if genetic 
testing continues, I would advocate adopting a precautionary approach, to monitor outcomes and 
further investigate clinical utility. This approach comprises a number of claims. Although 
determinism and discrimination are unlikely and no recipients of this test regretted their decision, 
given a lack of clear medical benefit the test should initially be used to inform clinical management 
in those who have experienced depression, rather than as a pre-symptomatic or predictive test.4 It 
should be offered in a clinical environment to competent consenting individuals who have had 
access to validated pre-test information and receive post-test follow-up. Testing using direct-to-
consumer methods should be discouraged and marketing should be carefully monitored. The test 
should not be offered to people experiencing an acute episode of depression, as receipt of the test 
result may later be associated with that depressive mood and the result may hinder recovery. 
Testing in younger children and for prenatal diagnosis is not currently supported by clinical evidence 
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or ethical arguments and will have little predictive value. Population screening for depression may 
be beneficial but the 5-HTT test is unlikely to be the best mechanism for this. Testing should also be 
accompanied by ongoing mixed methods survey research to examine post-test adjustment and 
engagement in ethical discussion by all stakeholders. 
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